Feedback PLC Board Changes (4796K)
29 August 2019 - 4:01PM
UK Regulatory
TIDMFDBK
RNS Number : 4796K
Feedback PLC
29 August 2019
Feedback plc
Board Changes
Cambridge, 29 August 2019: Feedback plc (AIM: FDBK, "Feedback"
or the "Company"), the specialist medical imaging technology
company, announces the appointment of Professor Rory Shaw as
non-executive Deputy Chairman of the Company, effective
immediately.
Non-executive Chairman, Dr Alastair Riddell, has informed the
Company that he intends to retire at the Company's next annual
general meeting. At such time, it is intended that Professor Rory
Shaw will be appointed non-executive Chairman of Feedback.
Professor Rory Shaw will step down immediately from his post as
Medical Director of Feedback Medical Limited, the Company's
operating subsidiary, which he has held since June 2018. The
functions of the post will be covered internally.
Professor Rory Shaw has extensive managerial and overseas trade
experience as well as a strong academic and clinical background. As
Medical Director of Feedback Medical, over the last year he has
contributed to the development of the Company's new strategy and to
building relationships with the UK medical community.
Professor Shaw was previously the Medical Director of Healthcare
UK within the Department of International Trade. Over the previous
15 years, he has been Medical Director of three NHS Trusts; North
West London Hospitals NHS Trust, the Royal Berkshire NHS Foundation
Trust and the Hammersmith Hospital NHS Trust. In 2001, he was
appointed by the then Minister of Health as the first Chairman of
the National Patient Safety Agency and was also a non-executive
director of the NHS Litigation Authority. Professor Shaw's clinical
specialty is respiratory and general medicine. He has been
published extensively in academic journals and was also a professor
of respiratory medicine at Imperial College School of Medicine.
Dr Alastair Riddell, Non-Executive Chairman of Feedback plc,
said:
"We welcome Professor Shaw to the Board after his successful
time as Medical Director of Feedback Medical. His extensive senior
level experience in the NHS and international network established
while with UKTI will help us to establish our new products within
the national and international medical community. He is an
eminently suitable replacement Chairman for me when I retire after
the next AGM".
Dr Tom Oakley, CEO of Feedback plc, commented:
"Dr Riddell has been a key force in driving Feedback forward in
recent years and on behalf of the Board, we are grateful for his
guidance and advice. He remains Chairman for the near term and
continues to work with the Board to oversee the launch of
Bleepa(TM) and the growth of the underlying operations.
"Professor Shaw's work with Feedback Medical has been vital in
helping us develop the next stage of our technology and the launch
of Bleepa(TM) . With his appointment as Deputy Chairman and in due
course, to Chairman, we will continue to benefit from his valuable
clinical and business expertise."
AIM Rules disclosures
Rory James Swanton Shaw, aged 65, is or has during the last five
years been, a director or partner of the following companies:
Current directorships/partnerships Former directorships/partnerships
within last five years
London Healthcare Consultancy Feedback Medical Limited
Ltd
As announced on 12 August 2019, Professor Rory Shaw has
conditionally subscribed for 4,166,667 ordinary shares in the
Company's recent placing and subscription to raise GBP2 million.
The placing and the subscription are subject to shareholder
approval at the general meeting of the Company to be held later
today and, if approved, Professor Shaw will have an interest in
approximately 0.77 per cent. of the Company's issued share capital
as enlarged by the placing and subscription.
-Ends-
Enquiries:
Feedback plc
Tom Oakley, CEO +44 (0)1954 718072
Lindsay Melvin, CFO IR@fbk.com
Allenby Capital Limited (Nominated
Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Capital Limited (Joint
Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited
(Joint Broker)
Patrick Claridge / John Howes +44 20 3815 8880
Instinctif Partners +44 (0)20 7457 2020
Rozi Morris / Phillip Marriage feedbackplc@instinctif.com
About Feedback plc
Feedback plc (AIM: FDBK) is a specialist medical imaging
technology company providing innovative software and systems,
through its fully-owned trading subsidiary, Feedback Medical
Limited. Its products advance the work of radiologists, clinicians
and medical researchers by improving workflows and giving unique
insights into diseases, particularly cancer. Feedback Medical works
with customers globally from headquarters in the internationally
renowned scientific hub of Cambridge, UK. Its proprietary
technologies are TexRAD(R) , the quantitative texture analysis tool
and Cadran, a picture archiving communication system (PACS). The
Company has recently announced the launch of its new messaging and
image transfer product Bleepa(TM). For more information, see
www.fbkmed.com/.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKVLFLKVFBBBV
(END) Dow Jones Newswires
August 29, 2019 02:01 ET (06:01 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Sep 2023 to Sep 2024